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Abstract
Lipoproteins are specialized particles involved in the transport and distribution
of hydrophobic lipids, as cholesterol and triglycerides, throughout the body. The
lipoproteins exhibit a basic spherical shape as complexes of lipids and proteins, and
these latter are known as apolipoproteins. Initially, the proteins associated with
lipoproteins were recognized as integral or peripheral proteins that only maintain
the dynamics and metabolism of lipoproteins. However, there exist many studies on
different lipoproteins evidencing that the quantity and type of apolipoproteins and
lipoprotein-associated proteins are diverse and could be associated with different
lipoprotein function outcomes. Here, we summarized recent processes in the deter-
mination of apolipoproteins and lipoprotein-associated proteins profiles through a
proteomic approach, analyzing the major methods available and are used to achieve
this. We also discuss the relevance of these lipoproteomic analyses on the human
disease outcomes.
Keywords: lipoproteins, lipoproteomic, proteomic, high density lipoproteins
(HDL), mass spectrometry (MS)
1. Introduction
The emerging high-throughput omics such as genomics, transcriptomics, prote-
omics, and metabolomics have been used in the search of new biomarkers in several
diseases. Proteomic analyses or metabolomics and lipidomics as well as comple-
mentary technologies such as mass spectrometry (MS) (i.e., LC-MS-MS and
MALDI-TOF/TOF), nuclear magnetic resonance spectroscopy, and other omics
technologies, are being widely used in the search of new sources of markers,
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candidates for vaccine, and alteration of expression patterns in response to envi-
ronmental changes and signaling pathways in different diseases. The search for
proteins in the dynamic system of a proteome requires various proteomics
approaches and the use of proteomics is crucial for the early disease diagnosis,
prognosis, and to monitor the disease development. The proteomics is essential for
the understanding of complex biochemical processes, and the high-throughput
proteomics increases the depth of proteome coverage.
Lipoproteins are macromolecular complex particles of lipids and proteins, which
are related to the extracellular transport of lipids in many organisms [1]. Besides,
lipoproteins have been also implicated as important host defense mediators and in
the initiation of immune responses [2–4]. Lipid content has long been recognized as
a critical factor in lipoprotein metabolism that acts as an important determinant of
human health [5]. However, in last years, apolipoproteins and lipoprotein-
associated proteins have been taken on relevance regarding lipoprotein metabolism
since they serve as a frame for their assembly, maintain their structure, and interact
with the membrane receptors and enzymes. Therefore, these proteins could be
crucial in the identification of biomarkers related to diseases due to the fact that
they are being studied under a global approach, denominated lipoproteome [6, 7].
2. Lipoprotein structure and metabolism
Lipoproteins are complex protein particles of an amphipathic nature, structur-
ally are formed by an outer layer of phospholipids, free cholesterol, and apolipo-
proteins, and inside contain a nucleus of cholesterol esters and triglycerides [8].
When the lipoprotein complex is formed, the orientation of the hydrophilic pro-
portions is toward the outside and the lipophilic proportions toward the interior;
this structural characteristic allows the complex to have the ability to emulsify fats
in extracellular fluids [8]. Based on their density defined by the protein to lipids
ratios, lipoproteins are grouped into six classes: chylomicrons, very low density
lipoproteins (VLDL), intermediate density lipoproteins (IDL), low density lipopro-
teins (LDL), high density lipoproteins (HDL), and lipoprotein (a) [Lp (a)] [8, 9].
Triglycerides, derived from dietary fat absorption by the small intestine, are
carried by the chylomicrons into blood. After triglyceride digestion to free fatty
acids (FFA) by lipases in the peripheral tissues, the size of these particles is reduced,
which leads to the formation of chylomicron remnants. These latter are cleared by
liver uptake via LDL receptor-related protein (LRP). To synthesize VLDL, newly
synthesized triglyceride and cholesterol by the liver are incorporated into chylomi-
cron remnants [8, 10]. These large triglyceride-rich VLDLs are released to the
circulation and travel to peripheral tissues, where the lipase digestion of triglycer-
ides occurs resulting in the IDL formation (VLDL remnants). These IDL particles
can be either cleared from the circulation by the liver in a similar manner to that
described for chylomicrons remnants or can be digested by hepatic lipase to gener-
ate cholesterol-rich LDL particles, which is taken up by the peripheral tissues via
LDL receptor to supply their cholesterol requirements [10].
The HDL lipoproteins have the highest relative density as compared to other
lipoproteins despite being the smallest in size and heterogeneous in terms of com-
position. These HDL particles play an important role in the transport of reverse
cholesterol as a carrier in the movement of cholesterol from peripheral tissues back
into the liver [11]. The liver and intestine, practically in response to the lipolysis of
triglyceride-rich lipoproteins, synthesize and secrete the nascent discoid HDLs that
consist primarily of phospholipids and free cholesterol. Then, these particles reach
the plasma where additional exchangeable apolipoproteins are picked up and excess
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free cholesterol is removed from both extrahepatic cells and other circulating lipo-
proteins, forming mature spherical HDL particles. Finally, these cholesterol-rich
HDL particles can be delivered back to the liver [10, 12].
The protein cargo related to lipoproteins consists of apolipoproteins and
lipoprotein-associated proteins. These proteins play key roles in lipoprotein metab-
olism such as structural component, enzyme interaction, and receptors recognition,
among other functions [7]. Changes in the quantity and type of these proteins could
be involved in the outcome of diseases related to lipid metabolism. Therefore, the
proteomic analysis of lipoproteins is an important notion for the present revision.
3. Apolipoproteins and lipoprotein-associated proteins
The apolipoproteins can be classified as integral or peripheral, either they act as
constituent components of the plasma membrane of the lipoproteins or they bind to
the membrane and can be exchanged between one complex and another, respec-
tively. Apolipoproteins are distributed throughout all lipoproteins and subfractions,
with the proportion of them varying in each family. These variations in the amount
of proteins present in the lipoprotein families in their membrane gives them their
capacity to interact with different tissues [7, 10].
Within the apolipoprotein A (ApoA) group is the apolipoprotein A-I (ApoA-I),
the main protein component of HDL, which plays multiple roles in the transport of
cholesterol, in addition to having been linked to the regulation of some functions of
the inflammatory and immune response [13]. ApoA-II, also found in HDL, acts as
an enzymatic inhibitor of lipoproteins and liver lipases. The apolipoproteins are
capable of binding to each other to modify the interaction of the lipoprotein com-
plex, as is the case with apoA-I and apoA-II in LDL [10].
ApoA-IV is mainly synthesized in the small intestine where it is attached by
enterocytes to the chylomicrons and secreted during a high-fat meal intake. ApoA-
IV is associated with HDL and chylomicron remnants in circulation, but a signifi-
cant portion is free [14]. On the other hand, ApoA-V participates in the regulation
of triglyceride levels in plasma [15]. ApoA-V is expressed only in the liver and
circulates at low concentrations. Despite this, apoA-V can be recovered in associa-
tion with plasma lipoproteins [16].
The apolipoprotein B (ApoB), the main protein component of chylomicrons,
LDL, VLDL, IDL, and Lp (a), is encoded by a single gene that gives rises to two
isoforms: ApoB-48 and ApoB-100. ApoB-48 is produced exclusively in the intestine
and is the major structural protein of chylomicrons and chylomicron remnants.
ApoB-100 is expressed in the liver and is found only in VLDL, IDL, LDL, and Lp
(a). ApoB-containing lipoproteins are characterized by a spherical shape and con-
tain one single apoB-48 or apoB-100 molecule per lipoprotein [17].
Apolipoprotein C (ApoC) works as an inhibitor of certain processes and modu-
lators of catabolism. ApoC is mainly synthesized in the liver and easily transferred
between lipoprotein particles and therefore are found associated with chylomi-
crons, VLDL, and HDL [10]. ApoC-I is responsible for inhibiting the binding of
lipoprotein to its receptor as well as the function of the esterified cholesterol trans-
fer protein (CETP). ApoC-II is an essential cofactor of the lipoprotein lipase
involved in triglyceride hydrolysis. Both apoC-III and apoC-IV inhibit triglyceride
hydrolysis. In addition, apoC-III decreases the clearance of VLDL [10, 18].
Several tissues synthesize apolipoprotein E (ApoE), an exchangeable apolipo-
protein associated with chylomicrons, chylomicron remnants, VLDL, IDL, and a
subgroup of HDL particles, but the liver and intestine are the principal producers of
circulating ApoE [10]. ApoE functions as a lipoprotein ligator with hepatocytes
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(clearance of apoE-containing lipoproteins) and peripheral cells related to the LDL
receptor. ApoCs and apoEs are interchangeable between complexes during the
conversion of VLDL to LDL. ApoEs may function as a lecithin-cholesterol
acyltransferase (LCAT) activator and influence the activity of hepatic lipase and
CETP [19, 20].
Proteins belonging to the lipocalins family such as apoD, apoM, the orosomucoid
protein, and retinol-binding protein (RBP) interact with the surface receptors of the
cells, intervening in the formation of macromolecular complexes. It has been
described that apoD binds to apoA-II and apoB-100 by means of disulfide bridges; it
is associated with LCAT, so it is involved in the transport of lipids in the blood
system. ApoJ is involved in a wide variety of processes, acting as a chaperone
protein and its main role is the inhibition of lipid transfer and is related to cell death.
There are apoproteins such as apoF whose function is unknown; however, there is a
theory of their role in abnormal lipid composition inhibiting CETP in the small and
dense LDL particles (sdLDL) [21, 22].
In addition to apolipoproteins, lipoproteins require other proteins with specific
activities to interact with the environment, which are denominated as lipoprotein-
associated proteins. Between these proteins are included phospholipase A2, whose
activity indicates the presence of sdLDL in plasma [23]. Serum amyloid A protein
(SAA) is associated with several lipoproteins, especially in LDL [24]. Some proteins
such as albumin and prenyl cysteine oxidase (PCYOX1) are responsible for
protecting against oxidation by lipoproteins such as LDL and splitting the thioether
bond of the prenyl cysteine generating H2O2, respectively. Also, proteomic studies
have identified the apoL-I, PON1, and PAF-AH in small amounts linked to the
complexes [25, 26].
The function of many of the proteins that interact with lipoproteins is still
unknown. The proteomic analyses have shown that the lipoprotein-associated pro-
teins are involved in cardiovascular risk, immune system, inflammatory processes,
among others [7, 26]. However, there is no guide for the analysis of lipoproteins at
the proteomic level basically because it depends on the biological question to be
investigated, and this determines the approach and the methods or tools to be used
as well as the technological platform to perform it.
4. Methodologies used for proteomic analysis of lipoproteins
Before describing the methodologies used for lipoproteomic studies, it is impor-
tant to mention some general characteristics of lipoprotein-associated proteins and
the importance of the research question to establish a good methodological flow
chart to address this question. We will start by mentioning that must first consider
the lipoprotein obtention by using methods for separation, concentration, and
protein stability due to the heterogeneity of these particles.
Diverse chromatographic techniques—prior to proteomic techniques—have
been used for the separation of plasma lipoproteins as well as the protein content,
such as capillary electrophoresis, size exclusion, cation exchange, gel filtration, fast
protein liquid, among other chromatographic techniques [7, 27–32].
The two-dimensional electrophoresis (2-DE) is one of the most usual methods
that have been applied to separate the protein cargo related to lipoproteins.
Although usually, the first-dimensional separation applied for the proteins in the 2-
DE is on base of their charge (isoelectrofocusing), some lipoproteomic analyses
have substituted this step by either one of the abovementioned methods to separate
lipoproteins or electrophoresis on native gels, followed by SDS-PAGE, which could
be denominated as gel-based lipoproteomics [27, 33–35].
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Pre-analysis Chromatography Mass spectrometry Analysis Post-analysis
Source Methods chromatographic
technique = Instrumentation
(method)
Mass
analyzer = Instrumentation
(method)
Database search Number of
lipoproteins and
apoproteins
References
Mice C57BL/6 J:
plasma
Gel filtration/size exclusion
chromatography,
phospholipid-containing
particles using CSH
LC-ESI = C18 reverse phase
column (GRACE; 150 
0.500 mm)
Quadrupole/TOF = 4800
scans, mass range: 300–
1800 m/z, charge states:2–5,
excluded target ions: 300 s
Swiss-Prot protein
knowledge base for
Mus musculus,
PeptideProphet algorithm
VLDL/LDL: 32, HDL:
104; lipid poor
lipoproteins: 55
[37]
Human serum (HDL) Trypsin, delipidation, gold
nanoparticles and LDI-MS,
EDX, SPE, FT-IR
MALDI-MS = nr Swiss-Prot, Lipidmaps
database
HDL (delipidation): 10
(prior), 6 (after). HDL
(anion exchangers): 23
[38]
Mice C57BL/6 J: apoA-I
KO and apoA-II KO,
apoA-I KO and WT:
plasma
Particles of CSH. Plasma
separation by size exclusion
chromatography
LC-ESI = column (C18 reverse
phase (150  0.500 mm))
Quadrupole/TOF = MS/MS.
tolerance were set to 35
PPM, and up to 3 missed
tryptic cleavage sites were
allowed
UniProtKB/Swiss-Prot
Protein Knowledgebase,
Peptide Prophet algorithm
HDL:WT:25 vs. ApoA-I
KO: 21; ApoA-II KO: 11
vs. WT: 14; and ApoA-
IV: 6 KO vs. WT: 7
[28]
17 Subjects (exposure
to organic pollutants):
plasma (HDL)
Ultracentrifugation
(290,000 g, 15°C, 4 h)
nLC: Column C18, ESI Linear ion trap-Orbitrap:
CID. ms/ms: 0.6 Da
MaxQuant v1.5.0, human
Uniprot/Swiss-prot
database
LCMS permit identified
the pathway of
interaction between
HDL-proteins
[39]
34 Men (2 dietary:
weight loss/high car):
plasma (LDL, ApoC-
III)
ELISA assay MALDI-TOF: 500 laser shots
mass spectra
Detection and
concentrations values
of 12 apoC-III
glycoforms
[40]
Mice (female, LDLr/
, 8 week old): plasma
(VLDL, LDL, HDL)
FPLC, ELISA assay LC Orbitrap: mass tolerance:
0.8 Da
Swiss-Prot database HDL: 91
LDL: 49
VLDL: 39
[41]
1000 Children (6–
8 years, Nepal rural
zone): plasma
Cation exchange
chromatography
LC Orbitrap Refseq 40 database Apo-AI, Apo-AII,
Apo-CIII
[42]
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Pre-analysis Chromatography Mass spectrometry Analysis Post-analysis
Source Methods chromatographic
technique = Instrumentation
(method)
Mass
analyzer = Instrumentation
(method)
Database search Number of
lipoproteins and
apoproteins
References
458 Children (6–
11 years, exposure to
environmental tobacco
smoke): serum (HDL,
LDL)
SPE-HPLC-TIS-MS/MS LC detected various
polyfluoroalkyl
substances in serum
A negative association
PFOS and non-HDL
[43]
57 Males (exposed to
arsenicum): plasma,
urinary (LDL, HDL,
Lp(a), Apo-A1, Apo-
B)
Centrifuged at 3500 rpm for
10 min
ICP-MS: extraction voltage
100 V, Rf power 1400 W,
focus voltage 12 V, and
nebulizer gas flow rate (using
a Burgener Miramist
nebulizer) 0.83 L/min. Dwell
times were 50 ms for 75As
and 10 ms for internal
standard (72 Ge)
ICP-MS: Potential risk
of the arsenic on
lipoproteins and
apolipoproteins
[44]
Human healthy,
normolipidemic males:
plasma (LDL)
Gel filtration
chromatography,
ultracentrifugation.
nLC: column (IntePepMap
100, C18, particle size 3 um),
flow rate = 300 nL/min
ESI: 2.5 kV, 150°C
Triple quadrupole TOF: mass
tolerance: 50 mDa, 350–
1800 m/z window, MSscan
type: 0.25 s
UniProtKB/Swiss-Prot
Protein Knowledgebase,
Peptide Prophet algorithm
LC-MS permit the
abundance protein as
well as antioxidant
activity
[30]
110 Samples
(purchased)
Phospholipids: UHPLC:
column (2.1 100 mm, 1.7 uM
particle), flow rate: 0.7 mL/
min, ESI
Qtrap: MRM scanning,
negative and positive mode
Multiquant software
functions, JMP (SAS
Institute)
LC-MS analysis of
serum/lipoproteins
[45]
23 Healthy volunteers:
serum
Gel filtration
chromatography, sequential
ultracentrifugation,
immunoassay
UPLC: column (UPLCR BEH
C8), floe rate: 450 uL/min.,
60°C, autosampler: 4°C ESI
Triple-quadrupole: positive
ion mode. Quantification of
plasmalogens: Capillary
voltage: 3500 V, source
temperature 80°C,
desolvation: 400°C, cone
voltage: 35 V. CE: 20–32 eV
LCMS: distribution of
each molecular species
in plasmalogen and
choline plasmalogen
[46]
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Source Methods chromatographic
technique = Instrumentation
(method)
Mass
analyzer = Instrumentation
(method)
Database search Number of
lipoproteins and
apoproteins
References
Healthy volunteers:
plasma (VLDL, LDL,
HDL)
Ultracentrifugation, SDS-
PAGE, size exclusion
chromatography, circular
dichroism, spectroscopy,
spectropolarimeter
MALDI-TOF: 337 nm
nitrogen laser, positive ion:
20 kV
Identification of
apolipoproteins
released from VLDL by
mass spectrometry
[47]
20 Patients with
lipoproteins (a) (18–
70 years): plasma
(LDL, HDL)
Ultracentrifugation, ELISA LC: solid-phase extraction Triple Quadrupole-linear ion
tramp: SRM. (energy
collision: 34 V, Q1: 786–788;
Q2: 1069–1072 m/z)
LC-MS system:
concentrations of lipid,
lipoprotein and
apolipoprotein
[48]
Healthy donors
(nonlipidemic, 24–
65 years, purchased
samples): plasma
(HDL, LDL)
Ultracentrifugation
(330,000 g, 6 h), SDS-
PAGE and Western
blotting, Negative stain
electron microscopy
UPLC: column (Kinetex
EVOC18), ESI
Triple-quadrupole: lipid
species were analyzed by
selected reaction monitoring
(from 141 to 369 m/z, from 0
to 50 eV)
Extraction and ionization
efficacy by calculating
analyte/ISTD ratios (AU)
and expressed as AU/mg
protein
LCS permit the
separation of a mixture
in HDL protein
[49]
12 Healthy male (36–
67 years): plasma
(HDL, LDL)
Ultracentrifugation
(40,000 rpm, 44 h, 15°C),
fractioned, apoA-I was
detected by Western
blotting, internal standars
HILIC-UHPLC-FLD: Glycan
chromatography column, 150
 2.1 mm i.d., 1.7 μm BEH
particles, flow rate of 0.56 mL/
min
MALDI-TOF-MS: 25 kV,
acceleration voltage: 140 ns
extraction delay, mass
window: 1000–5000 m/z.
For each spectrum: 10,000
laser shots, laser frequency of
2000 Hz
LDL: 18
HDL: 22
N-glycome of human
plasma lipoproteins
[50]
16 Healthy adults:
plasma (HDL, apoA-I,
apoB)
Ultracentrifugation. PRM
analysis (shotgun
proteomics experiments).
UPLC: flow rate: 0.6 uL,
column (Xbridge BEH C18)
ESI
Orbitrap: PRM mode,
isolation window: 2 Th, HCD:
27%, orbitrap analyzer:
15,000 resolution, AGC: 5 
104, maximum ion time
30 ms
PeptideAtlas mass spectral
database
Meal macronutrient
content HDL
composition in the
postprandial state
[51]
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Pre-analysis Chromatography Mass spectrometry Analysis Post-analysis
Source Methods chromatographic
technique = Instrumentation
(method)
Mass
analyzer = Instrumentation
(method)
Database search Number of
lipoproteins and
apoproteins
References
47 Volunteers: serum
(HDL, non-HDL).
Anti-apoAI magnetic
nanoparticles (10 mg) and
serum (5 μl) were mixed
FTIR, X-ray diffraction
ID/LC/MS system:
LC: column (waters symmetry
C18), flow rate: 0.3 mL/min.
APCI: corona current: 5 uA,
source temperature: 450°C
API 4000 tandem mass
spectrometer (triple-
quadrupole): Collision
energy: 26 eV, collision exit
potential: 6 V
ID/LC-MS permit the
monitoring serum in
clinical settings to
dyslipidemia and
atherosclerosis
[52]
SRM: selected reaction monitoring. HPLC: high performance liquid chromatography. HILIC-UHPLC-FLD: hydrophilic-interaction ultra-high-performance liquid chromatography with fluorescence detection.
LC: liquid Chromatography. UPLC: ultra-performance liquid chromatography. MALDI: matrix-assisted laser desorption/ionization. TOF: time of flight. Qtrap or LTQ linear trap: triple quadrupole-linear
ion trap. CE: collision energy. MS/MS: tandem mass spectrometry. PRM: parallel reaction monitoring. AGC: automatic gain control. ID/LC/MS: isotope dilution liquid chromatography mass spectrometry.
ESI: electrospray. nESI: nano-electrospray. FPLC: fast protein liquid chromatography. MRM: multiple reaction monitoring. HILIC: silica-based and solid-core reverse phase after hydrophilic interaction. ICP-
MS: Inductively coupled plasma-mass spectrometer. SPE: solid phase extraction. SPE-HPLC-TIS-MS/MS: solid phase extraction coupled to high performance liquid chromatography-turbo ion spray
ionization-tandem mass spectrometry. SEC-FPLC: size exclusion chromatography by fast protein liquid chromatography. APCI: atmospheric pressure chemical ionization. CID: collision-induced dissociation.
LDI-MS: laser desorption/ionization mass spectrometry, EDX: dispersive X-Ray Spectroscopy. CSH: calcium silica hydrate. WT: wild-type. KO: knockout. FTIR: Fourier transformation infrared.
Table 1.
Chromatographic and spectrometric methodologies used recently in lipoproteomic analysis.
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Pre-analysis | Spectroscopy
experiment NMR
type
Post-analysis References
Source isolation method
133 Caucasian
participants (T2DM,
>18 years): serum
(VLDL, LDL, and
HDL)
1H: FT, 400 MHz Determinate the
lipoprotein subtraction
characteristics
[56]
98 people (T2DM/
nor T2DM): plasma
(GlycA vs. Lp-PLA2)
Centrifugation
(1400 g, 15 min)
1H: 400 MHz, 47°
C, CaEDTA
resonance at
2.519 ppm was
used as the
internal chemical
GlycA is correlated with
LP-PLA2 in plasma
(person without T2DM/
MetS)
[57]
23 patients with
primary
aldosteronism: plasma
(HDL, VLDL, LDL,
ApoB, and ApoA-I)
Immunoturbidimetric
assay
1H: 400 MHz, 47°
C. (LipoProfile-3
algorithm)
Circulating LDL may
contribute to adrenal
steroidogenesis in
humans
[58]
115 nondiabetic
women (35–55 years,
mediterranean diet,
physical exercise,
2 years): plasma
(HDL. LDL)
1H Lipoprotein size,
particle and subclass
concentrations
[54]
Human serum
(purchased) spiked
into phlebotomy
tubes (LDL, HDL)
Centrifugation
(3000 g, 5 min, 4 h)
1H: 600 MHz Lipoprotein subclass
analysis standardized
by tube type and tube
size to prevent risk of
analytical interference.
[59]
Patients with HFrEF
(782), HFpEF (1004),
and no HF (4742):
plasma (HDL)
NMR LipoProfile-
3 algorithm
Quantify
concentrations of HDL.
Phenotyped cohorts of
HFrEF, HFpEF, and
patients without HF
[60]
4897 subjects: plasma
(LDL)
1H: 400 MHz Differentiate in the size
of particle in LDL
profile
[61]
309 patients (MACE):
plasma (HDL, LDL,
and VLDL).
Control:902
1H Neither baseline HDL
nor the change in HDL
on treatment with
dalcetrapib or placebo
was associated with risk
of MACE after ACS
[62]
Normal volunteer:
plasma (HDL, LDL,
andVLDL)
Sequential
ultracentrifuge
1H, 13C, 15N:
600.55 MHz, 47°
C, different
pressures
Show the spatial
arrangement, phase
behavior and molecular
dynamics in the particle
core
[55]
3446 participants
(HDL, LDL, and
VLDL)
1H: LipoProfile-3
algorithm
Association between
FGF21 and NAFLD
[63]
MHz: megahertz (106). MetS or MS: metabolic syndrome. T2DM: type 2 Diabetes mellitus. FT: Fourier transforms.
CaEDTA: EDTA mono calcium. GlycA: glycoprotein acetylation. Lp-PLA2: lipoprotein-associated phospholipase A2.
HFrEF: reduced ejection fractions. HFpEF: preserved ejection fraction. HF: heart failure. MACE: major adverse
cardiovascular events. FGF21: fibroplast growth factor21. NAFLD: nonalcoholic fatty liver disease.
Table 2.
NMR methodology applied recently in lipoprotein-based analyses.
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Lipoprotein-associated proteins are not easy to study by proteomic methods,
mainly the embedded in the lipoprotein membranes. These latter have rigid trans-
membrane domains that contain α-helices or β-barrels, which stabilize the protein
by strong secondary structural characteristics and these regions can resist proteo-
lytic digestion [6, 36]. Thus, the protein identification for lipoproteomes has been
mainly performed by two methods: mass spectrometry and resonance magnetic
nuclear.
Modern mass spectrometry (MS) techniques have allowed for thorough charac-
terizations of the lipoproteins [37]. However, different experimental conditions
have been reported to avoid contamination of the biological samples as well as
selective and optimized methods to detect lipoproteins, usually liquid-phase sepa-
ration techniques, prior to spectrometric techniques [36, 37]. Thus, different spec-
trometric experimentation conditions have been reported for the study of
lipoproteins and apoproteins, respectively (Table 1).
There are several challenges in the lipoproteomic analyses performed with the
most advanced mass spectrometry methods. Some of them are the abundance of
proteins from the biological source and the lipoprotein(s) purification steps, which
conditioned the protein content and constitution. However, if this obstacle can be
overcome, the mass spectrometry analysis has been demonstrated to be a useful tool
to identify a diverse array of proteins related to lipoproteins, avoiding aberrant
integration of unexpected proteins by reducing the suppression of ionization at high
peptide resolution [53].
On the other hand, the nuclear magnetic resonance (NMR) technique permit,
besides protein identification, can provide information of the lipoproteins at both
molecule and atomic levels under physiological or ‘near-physiological’ conditions.
The signal most used to quantify lipoproteins is the methyl signal because give a
specific response in the lipids that travel inside the lipoproteins [54, 55]. In this way,
proton spectroscopy has been the most used nuclear magnetic resonance technique
to quantify lipoproteins, but it is not the only one as will be seen later (Table 2).
Furthermore, not only 1H NMR has been the technique used for the study of
lipoproteomics but also the two-dimensional NMR techniques have been used.
The two-dimensional heteronuclear 13Cd1H chemical-shift made it possible to
analyze macromolecular complexes like HDL, but with a limited resolution in
reduced peaks above 50 ppm and the limited resolution in the 29–33 ppm region,
inclusive with artifacts that would later be discarded by the spectra of one
dimension (1H and 13C) [64].
In addition, the material to be used for the spectroscopic analysis should be the
optimal one to avoid contamination, as in the case of a tube used for the collection
of biological material and used in clinical research, which should be specifically for
the analysis of lipoproteins [59].
Also, the experimental conditions do not always favor the use of NMR for the
analysis of lipoproteins. Thus, mass spectrometry permits the particle identification
via LC-MS system in contrast to NMR spectroscopy, which failed. Due to that, the
NMR spectroscopy makes HDL particle quantification only in a physiological set-
ting: full serum or plasma but not in HDL-containing suspensions [49]. Therefore,
the technician must consider the biological and technical variables for an assertive
lipoproteomic analysis.
5. Clinical significance of lipoproteomic analyses
The lipoproteomic analyses have been focused on understanding the functional
mechanisms underlying apolipoproteins and lipoprotein-associated proteins that
10
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can be used to develop new diagnostic and/or prognostic biomarkers for many
lipoproteins’ metabolism-related illness.
The HDL lipoprotein fraction has been the most studied according to
lipoproteomic relationships with different diseases. Among the HDL-associated
proteins, ApoC-III levels have been seen increased in the patients with either a
lupus nephritis (lupus erythematosus) or with a cerebral lacunar infarction, which
could be related with a reduced anti-inflammatory activity of HDL particles
[65, 66].
However, HDL-carried ApoC-III has been more implicated in cardiovascular
disease (CVD) risk. One of the first evaluations was performed with coronary artery
disease patients, which exhibit increased levels of ApoC-III [67]. Recently, in a
cohort study, it was demonstrated that HDL-carried ApoC-III is related to a higher
risk for coronary heart disease [68].
In addition to ApoC-III and ApoC-II, other HDL-associated apolipoproteins,
were proposed as biomarkers for CVD risk in patients with chronic hemodialysis
[69]. The ApoC-III/ApoC-II/ApoE levels in VLDL lipoproteins, independent of
HDL, were associated with incident CVD, which supports the concept of targeting
triacylglycerol-rich lipoproteins to reduce the CVD risk [70].
Other HDL-associated apolipoproteins have been associated with cardiac
pathologies. For example, ApoA-I, ApoA-IV, ApoE, and ApoL1 levels have been
seen enriched in HDL3 fraction from patients with acute coronary syndrome
(ACV), with a concomitant reduction of these apolipoproteins in the HDL2 fraction
[71]. Furthermore, ApoC-I was significantly decreased in the HDL particles of
coronary heart disease (CAD) patients in comparison to normal individuals [72].
The existence of CAD has recently been correlated with an HDL apolipoproteomic
score, independent of circulating ApoA-I and ApoB rates and other typical cardio-
vascular risk factors [73].
Regarding HDL-associated proteins, many of them have been related to heart
illness. For example, serotransferrin, haptoglobin, hemopexin, complement factor
B, ras-related protein Rab-7b, and paraoxonase-3 (PON3) levels have been seen
reduced in HDL from patients with some cardiac pathology. Meanwhile, PON1,
alpha-1B-glycoprotein, vitamin D-binding protein, alpha-1-antitrypsin (A1AT),
acid ceramidase, serum amyloid A and P proteins, sphingosine-1-phosphate, filamin
A, and pulmonary surfactant-associated protein B are increased in HDL fractions
from patients with cardiometabolic disorders [69, 71, 72, 74, 75].
Diabetes is, perhaps, the major controllable risk factor for CVD. In particular,
related to the HDL fraction, ApoA-I, ApoA-II, ApoA-IV, ApoE, ApoJ, as well as
PON1, transthyretin, complement C3, and vitamin D-binding protein have shown
changes in patients with type 2 diabetes (T2D) [76, 77]. In contrast, individuals with
type 1 diabetes (T1D) had proteomic alterations of their HDL particles. For exam-
ple, the complement factor H-related protein 2 was elevated, independent of glu-
cose control, in T1D patients in comparison to healthy controls. Also, the optimal
glucose control corrected the elevated levels of the alpha-1-beta glycoprotein and
inter alpha trypsin inhibitor 4. Furthermore, the HDL particles in T1DM individ-
uals, independent of glucose control, exhibit a higher abundance of irreversible
post-translational modifications of HDL-associated apolipoproteins [78, 79].
Also, in psoriatic patients, the levels of HDL-associated ApoA-I exhibit a signif-
icant reduction, whereas levels of apoA-II, serum amyloid A, C3, and A1AT, among
other proteins were increased [80]. Besides C3 and C9, complement factor B, as
well as ApoJ, fibrinogen, haptoglobin, and serum amyloid A have been also
increased in HDL fraction from patients with rheumatoid arthritis [81]. Taken
together, these results suggest that HDL-associated proteins could be involved in
anti-inflammatory properties in chronic illness.
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Concerning other diseases, the proteome of HDL particles has been used to
identify protein markers. In nonalcoholic fatty liver disease, including individuals
with nonalcoholic steatohepatitis, changes in the abundance of HDL-associated
proteins such as antithrombin III and plasminogen have been identified [82].
Although not directly to HDL particles, proteomic analysis of some HDL-related
apolipoproteins has been associated with viral diseases. For example, a change in
the expression level of ApoA-I was suggested as a specific and appropriate alterna-
tive to conventional HIV diagnosis and progression measurements in clinical
research settings [83]. Increased concentration of ApoM in sera patients with HBV
infection have been detected [84]. Recently, a downregulation of ApoA-I and ApoM
levels have been associated with the severity of COVID-19 infection [85].
In addition to HDL, only other few lipoproteomic studies have been developed
to discover changes in lipoproteins-associated proteins in diverse pathologies.
Proteomic studies of LDL have reported that carry apolipoproteins AI, A-II, CI,
C-II, C-III, C-IV, D, E, and F, in addition to apoB, as well as clusterin, C3, C4a, and
C4b, and PON1 that are also associated to this particles [86]. Serum amyloid A
levels were found to increase in all lipoprotein fractions, especially in LDL from
atherosclerotic patients [24]. An enriched content of all the apoC-III isoforms and a
lower content of apoA-I, apoC-I, and apoE were detected in the sdLDL from
subjects with metabolic syndrome and subclinical peripheral atherosclerosis [87].
VLDL, IDL, and LDL fractions from Alzheimer patients exhibit low levels of
complement C3 [88].
6. HDL lipoproteomics for drug discovery
Target discovery, which is an important step in the drug development process,
includes discovering and validating targets associated with the diseases. It is
increasingly recognized that, in many instances, metabolomics is used to identify
novel biomarkers, which can help in the discovery of therapeutic strategies for
many diseases [89].
Until now, lipoproteomics has proved to be an effective method for identifying
candidate cardiovascular disease markers. Studying the profiles of protein expres-
sion in drug-treated patients contributes to the discovery of multiple drug-specific
targets. Traditionally, statin therapy has proven efficacy in reducing cardiovascular
events, but as aforementioned, the identification of HDL-associated proteins is
variable. The statin therapy has a notorious effect on the increment of A1AT
associated to the large fraction of HDL particles enhancing its anti-inflammatory
functionality, which may interfere with the statins outcome on reducing cholesterol
levels [37]. In addition, a relationship between the CAD treatment and the HDL
proteome was demonstrated using statin and niacin therapy, observing that ApoE
and ApoC-II levels are enriched in the HDL3 fraction, which contains less ApoJ
levels [90].
The increment in the HDL levels by CETP inhibitors is another biomarker that
has continued to be disappointing in clinical research. In fact, in patients with
deficiency of CETP (CETP-D), the HDL particles are enriched with ApoE,
angiopoietin-like3 protein, and complement regulatory proteins such as C3, C4a,
C4b, and C9 that could be associated to the increased atherogenic profile in CETP-D
patients [91].
Thus, it is important to consider that among the diverse HDL populations not all
possess a cardioprotective effect [92]. Therefore, we need a better knowledge of the
protein cargo of the HDL populations with anti-atherogenic actions. A comprehen-
sive understanding of the HDL proteomics can lead to the design of more effective
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anti-atherogenic drugs based on the activity of HDL-associated proteins that will
provide new therapeutic strategies at the molecular level.
In the dynamic drug discovery process, the different proteomic methods, which
include MS-proteomics, expand beyond the general aim of target drug discovery. It
must consider the drug-protein interactions as well as elucidate the mode of action
of candidate drug molecules [93]. Thus, novel HDL-based therapeutic agents,
besides the traditional statins, will need consider to the functional HDL
lipoproteomics to characterize the interaction of the drug with the HDL-associated
proteins. This is necessary as an attempt either to elucidate the mechanism of action
by direct drug-protein interaction or as a biomarker for drug validation by moni-
toring the pharmacological effect through an increase of HDL populations with an
anti-atherogenic protein cargo.
7. Conclusion
The lipoproteins can be involved in different pathologies related to lipid metab-
olism such as atherosclerosis, cardiovascular risk, obesity, metabolic síndrome, and
diabetes, among others. However, the protein cargo of these particles has been
associated with several functions, which differ from the amply recognized as struc-
tural composition and receptors recognition during their function as lipid trans-
porters. For this reason, the identification of variants of apolipoproteins and
lipoprotein-associated proteins has been an important referent to detect new bio-
markers. In fact, as we described here, several methodologies have been developed
to improve the lipoproteomic profile.
Despite these studies, the majority concord that both biological source and
lipoprotein purification are important steps to avoid protein contamination, princi-
pally from samples that are used directly as serum or plasma. Also, the most used
method to identify the lipoprotein-associated proteins is the mass spectrometry, but
some limits are presented that depend on the platforms to apply this methodology.
Also, it is important to highlight that not everyone has the facility to use this
methodology and it is necessary to develop new methodologies to apply in clinical
fields to ensure discoveries about these proteins both in new lipoproteins’ fractions
and new diseases.
Also, the lipoproteomic analyses could be a new clinical area to evaluate the
therapy of the pathologies described here as prognostic analytes. In this sense, the
HDL lipoproteomics is, perhaps, the more advanced field considering the evalua-
tions of populations with statins’ treatment. However, novel HDL therapeutic
agents must consider the functional lipoproteomics of these particles. Finally, these
lipoproteomes can help us to describe the molecular mechanism to understand the
interaction of apolipoproteins as well as the lipoprotein-carried proteins to support
the other omics such as lipidomics and metabolomics.
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